
Alpa Laboratories Analyst Review 2027: Sales Rise 10% but Q2 Swings to a Loss
Updated: 19 Nov 2026 • 2:04 pm
Posted by:

Alpa Laboratories Stock Snapshot (18 Nov 2026 close)
- Current Market Price (CMP): ₹51.59
- 52-Week High / Low: ₹92.50 / ₹46.10
- Market Capitalisation: ₹109 crore
- P/E Ratio vs Industry P/E: 51.6 vs 40.1
- Latest Quarter (Q2 FY27) Revenue: ₹32.22 crore
- Latest Quarter (Q2 FY27) Net Profit: Loss of ₹1.85 crore
Quick Answer: The Alpa Laboratories analyst review 2027 finds no brokerage coverage as of November 2026. Q2 FY27 sales rose about 10% to ₹32.22 crore, but EBITDA turned negative at minus ₹0.99 crore and the company posted a net loss of ₹1.85 crore, against a small profit a year ago. FY26 revenue was ₹121.6 crore with profit of ₹15 crore. The stock closed at ₹51.59, about 44% below its 52-week high, and trades at about 0.58 times book value, so the Alpa Laboratories share price target 2027 question depends on a return to operating profit.
The Alpa Laboratories analyst review 2027 covers an Indore-based maker of finished medicines such as injections, tablets, capsules and ointments, sold under its own brand, through contract manufacturing and in export markets. Readers searching for an Alpa Laboratories share price target 2027 will not find a named brokerage figure, so results and book value guide this review.
Alpa Laboratories closed at ₹51.59 on 18 November 2026, about 44% below its 52-week high of ₹92.50 and about 12% above its low of ₹46.10. This Alpa Laboratories analyst review 2027 covers the September quarter and the Alpa Laboratories stock outlook 2027.
Click Here – Get Free Investment Predictions
What Analysts Say in the Alpa Laboratories Analyst Review 2027
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| No verified coverage | Not available | Not available | As of November 2026 |
No brokerage covers Alpa Laboratories, and institutions hold less than 0.5% of the company. With a market value of about ₹109 crore, it sits outside research coverage.
Book value is the clearest reference point. Book value per share is about ₹88.36, well above the share price, so the market values the company at about 0.58 times net worth. This Alpa Laboratories analyst review 2027 explains why that discount has widened.
Q2 FY27 Results in the Alpa Laboratories Analyst Review 2027
| Quarter | Revenue | EBITDA | Net Profit |
|---|---|---|---|
| Sep 2026 (Q2 FY27) | ₹32.22 crore | Minus ₹0.99 crore | Loss of ₹1.85 crore |
| Jun 2026 (Q1 FY27) | ₹29.70 crore | ₹1.81 crore | ₹0.98 crore |
| Mar 2026 (Q4 FY26) | ₹31.24 crore | ₹3.44 crore | ₹1.38 crore |
| Dec 2025 (Q3 FY26) | ₹29.96 crore | ₹2.42 crore | ₹1.59 crore |
| Sep 2025 (Q2 FY26) | ₹29.32 crore | ₹0.82 crore | ₹0.11 crore |
Revenue rose about 10% from a year ago and about 8% from the June quarter, but EBITDA turned negative at minus ₹0.99 crore. The company posted a net profit loss of ₹1.85 crore, its weakest quarter in the table.
Higher sales with an operating loss points to cost pressure, such as raw materials, staff or new capacity costs. For this Alpa Laboratories analyst review 2027, the December quarter will show whether this was a one-off.
How Alpa Laboratories Makes Money
Alpa makes finished dosage forms at its plant near Indore.
- Own brand: generic, over-the-counter and veterinary medicines sold under the Alpa name.
- Contract manufacturing: production for other pharma companies.
- Injections and liquids: liquid and dry powder injections, among other forms.
- Exports: sales to markets in Africa, Asia and Latin America.
FY26 revenue was about ₹121.6 crore with profit of about ₹15 crore, against ₹135.8 crore and ₹19.5 crore in FY25. Operating cash flow was about ₹9.3 crore in FY26. Those numbers frame this Alpa Laboratories analyst review 2027.
Annual profit has been much higher than recent quarters suggest. The four quarters from December 2025 to September 2026 add up to only about ₹2.1 crore of profit, compared with ₹15 crore for FY26 as a whole. That points to a large contribution from one earlier quarter or from non-operating income, so the core business currently earns far less than the annual figure implies.
Small formulation makers face pricing pressure from larger rivals, and contract manufacturing margins depend on how fully the plant is used. Export orders can also be lumpy, so revenue and margins can move sharply between quarters.
The company has been carrying out a capital spending programme to add capacity. New capacity often adds costs before it adds revenue, so margins could stay under pressure until the expansion starts contributing to sales.
The balance sheet is almost debt-free, with debt to equity of about 0.01, so the losses do not create immediate financial strain. The issue is return on equity, which has fallen to about 1.1%, the main reason the stock trades well below book.
Growth Triggers in the Alpa Laboratories Analyst Review 2027
- Sales growth: Q2 FY27 revenue up about 10%.
- Debt-free: debt to equity near zero.
- Capacity additions: new capacity could lift volumes over time.
- Export reach: sales across several emerging markets.
- Discount to book: about 0.58 times book feeds the Alpa Laboratories share price target 2027 debate.
Key Risks in the Alpa Laboratories Analyst Review 2027
- Operating loss: EBITDA turned negative in Q2 FY27.
- Weak core earnings: about ₹2.1 crore profit over four quarters.
- Low returns: return on equity of about 1.1%.
- Pricing pressure: competition from larger drug makers.
- Share price fall: about 44% below its high, a caution in the Alpa Laboratories analyst review 2027.
Compare Alpa Laboratories With Other Pharma Stocks on the Univest Screener
Alpa Laboratories Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (18 Nov 2026 close) | ₹51.59 |
| 52-Week High / Low | ₹92.50 / ₹46.10 |
| Market Capitalisation | ₹109 crore |
| P/E (TTM) | 51.6 |
| Price to Book | 0.58 |
| Book Value per Share | ₹88.36 |
| Return on Equity | 1.1% |
| Debt to Equity | 0.01 |
| EPS (TTM) | ₹1.00 |
| FY26 Revenue / Net Profit | ₹121.6 crore / ₹15.0 crore |
The P/E of about 52 looks high only because trailing earnings have fallen sharply. Price to book value of 0.58 is the more useful measure. In this Alpa Laboratories analyst review 2027, returns need to recover before the discount can narrow.
Shareholding Trend
| Holder | Sep 2025 | Sep 2026 | Change |
|---|---|---|---|
| Promoters | 57.29% | 57.19% | Down 0.10 points |
| Foreign Investors (FII) | 0.35% | 0.35% | No change |
| Domestic Institutions (DII) | 0.00% | 0.07% | Up 0.07 points |
| Public | 42.35% | 42.39% | Flat |
The promoter group holds about 57.2%, led by managing director Paresh Chawla at 34.3% and Shitul Shah at 10.2%. Stable holdings are a neutral point in the Alpa Laboratories analyst review 2027.
What to Watch After the Alpa Laboratories Analyst Review 2027
- December quarter: a return to positive EBITDA.
- Margins: recovery towards earlier levels.
- Capacity: progress on the capital spending plan.
- Exports and contracts: new orders that lift plant use.
- Coverage: any research note would give an Alpa Laboratories share price target 2027 reference.
Final Word on the Alpa Laboratories Analyst Review 2027
The Alpa Laboratories analyst review 2027 shows a debt-free drug maker with growing sales but an operating loss in Q2 FY27 and weak core earnings. The stock trades near its 52-week low and well below book value.
The Alpa Laboratories stock outlook 2027 depends on restoring margins and lifting returns. Univest does not give a buy or sell call.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Alpa Laboratories analyst review 2027 show?
It shows higher sales but a loss. Q2 FY27 revenue rose about 10% to ₹32.22 crore, but the company posted a net loss of ₹1.85 crore. EBITDA was minus ₹0.99 crore.
Is there an Alpa Laboratories share price target 2027 from brokerages?
No brokerage covers Alpa Laboratories as of November 2026. The stock closed at ₹51.59 on 18 November 2026. Book value per share is about ₹88.36.
What does Alpa Laboratories make?
Alpa makes finished medicines such as injections, tablets, capsules and ointments at its Indore plant. It sells under its own brand, does contract manufacturing and exports. FY26 revenue was about ₹121.6 crore.
Why did Alpa Laboratories post a loss in Q2 FY27?
Operating costs rose faster than sales, turning EBITDA negative at minus ₹0.99 crore. Revenue still grew about 10%. The four quarters to September 2026 earned only about ₹2.1 crore in total.
Is Alpa Laboratories stock undervalued based on the Alpa Laboratories analyst review 2027?
The stock trades at about 0.58 times book value. Return on equity has fallen to about 1.1%. The P/E of about 52 reflects depressed earnings.
What risks does the Alpa Laboratories analyst review 2027 highlight?
The main risks are the operating loss, weak core earnings and pricing pressure. The stock is about 44% below its 52-week high of ₹92.50. Returns are very low.
What should investors track after the Alpa Laboratories analyst review 2027?
Track whether EBITDA turns positive in the December quarter. Watch margins, progress on new capacity and new export or contract orders. Return on equity also matters.
Recent Articles

Futures Basis Contango and Backwardation Explained: What the Gap to Spot Shows, Why Futures Trade at a Premium and How to Read It
19 November 2026

Physical Settlement vs Cash Settlement Explained: How Stock and Index Derivatives Settle, What Happens at Expiry, Margin Impact and How to Avoid Delivery
19 November 2026

Broken Wing Butterfly Explained: How the Uneven Wings Work, Payoff, Break-Even, Where Maximum Profit and Loss Sit and When Traders Use It
19 November 2026

Jade Lizard Strategy Explained: How the Three Leg Setup Works, Payoff, Break-Even, Why Upside Risk Is Removed and When Traders Use It
19 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Futures Basis Contango and Backwardation Explained: What the Gap to Spot Shows, Why Futures Trade at a Premium and How to Read It
Physical Settlement vs Cash Settlement Explained: How Stock and Index Derivatives Settle, What Happens at Expiry, Margin Impact and How to Avoid Delivery
Broken Wing Butterfly Explained: How the Uneven Wings Work, Payoff, Break-Even, Where Maximum Profit and Loss Sit and When Traders Use It
Jade Lizard Strategy Explained: How the Three Leg Setup Works, Payoff, Break-Even, Why Upside Risk Is Removed and When Traders Use It
Ultimate Oscillator Explained: Formula, Three Time Frames, Overbought and Oversold Levels, Divergence Signal Rules and Where It Misleads
Popular this week
Island Reversal Pattern Explained: How the Gaps Form, Bullish and Bearish Versions, Volume Clues, Entry Rules and Where It Fails

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





